A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice.
Consensus StatementСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bettenworth Dominik, Baker Mark E, Fletcher Joel G, Jairath Vipul, Lu Cathy, Bemelman Willem, d'Haens Geert, d'Hoore Andre, Dignass Axel, Dotan Iris, Feakins Roger, Fleshner Phillip, Ha Christina, Henderson Gaylyn, Lyu Ruishen, Panes Julian, Rogler Gerhard, Mao Ren, Rimola Jordi, Sandborn William J, Ng Siew C, Siegmund Britta, Silverberg Mark, Taylor Stuart A, Verstockt Bram, Gordon Ilyssa O, Bruining David H, Feagan Brian G, Rieder Florian, Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium
Аннотация
Fibrostenosis of the small bowel is common in patients with Crohn's disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement, we present a clinical practice RAND/UCLA appropriateness study on the definition, diagnosis and clinical management of fibrostenosing Crohn's disease. It was conducted by a panel of 28 global experts and one patient representative. Following a systematic literature review, 526 candidate items grouped into 136 questions were generated and subsequently evaluated for appropriateness. Strictures are best defined as wall thickening, luminal narrowing and prestenotic dilation. Cross-sectional imaging is required for accurate diagnosis of fibrostenosing Crohn's disease, and it is recommended before making treatment decisions. It should also assess the degree of inflammation in the bowel wall. Multiple options for medical anti-inflammatory, endoscopic and surgical therapies were suggested, including follow-up strategies following therapy. This Consensus Statement supports clinical practice through providing guidance on definitions, diagnosis and therapeutic management of patients with fibrostenosing small bowel Crohn's disease.